E. Salinas

443 total citations
22 papers, 105 citations indexed

About

E. Salinas is a scholar working on Obstetrics and Gynecology, Reproductive Medicine and Cancer Research. According to data from OpenAlex, E. Salinas has authored 22 papers receiving a total of 105 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Obstetrics and Gynecology, 12 papers in Reproductive Medicine and 7 papers in Cancer Research. Recurrent topics in E. Salinas's work include Ovarian cancer diagnosis and treatment (12 papers), Endometrial and Cervical Cancer Treatments (11 papers) and Genetic factors in colorectal cancer (5 papers). E. Salinas is often cited by papers focused on Ovarian cancer diagnosis and treatment (12 papers), Endometrial and Cervical Cancer Treatments (11 papers) and Genetic factors in colorectal cancer (5 papers). E. Salinas collaborates with scholars based in United States, Spain and Belgium. E. Salinas's co-authors include Michael J. Goodheart, Jesús González Bosquet, Kimberly K. Leslie, Eric J. Devor, A.M. Newtson, Kristina W. Thiel, Bruce A. Smith, David Bender, Christine Gennigens and Susana Banerjee and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Annals of Oncology.

In The Last Decade

E. Salinas

20 papers receiving 104 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Salinas United States 6 51 43 35 34 23 22 105
Vladimir Nosov Russia 3 87 1.7× 50 1.2× 29 0.8× 36 1.1× 16 0.7× 6 134
Maria Pilar Barretina-Ginesta Spain 6 69 1.4× 49 1.1× 58 1.7× 49 1.4× 53 2.3× 9 151
Ginés Hernández-Cortes Spain 5 93 1.8× 56 1.3× 33 0.9× 28 0.8× 30 1.3× 8 179
Emma Titmuss Canada 7 17 0.3× 36 0.8× 23 0.7× 31 0.9× 44 1.9× 21 104
Kelly K. Foy United States 4 36 0.7× 71 1.7× 44 1.3× 27 0.8× 23 1.0× 4 142
Anne Sophie V M van den Heerik Netherlands 4 61 1.2× 43 1.0× 101 2.9× 35 1.0× 19 0.8× 4 151
Daliah Tsoref Israel 6 52 1.0× 66 1.5× 56 1.6× 33 1.0× 59 2.6× 15 166
Alexandra Tyulyandina Russia 6 40 0.8× 50 1.2× 17 0.5× 14 0.4× 47 2.0× 37 114
Zong-Min Fan China 6 20 0.4× 69 1.6× 23 0.7× 38 1.1× 17 0.7× 12 136
Eugenia Ortega Spain 6 20 0.4× 42 1.0× 25 0.7× 36 1.1× 44 1.9× 9 114

Countries citing papers authored by E. Salinas

Since Specialization
Citations

This map shows the geographic impact of E. Salinas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Salinas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Salinas more than expected).

Fields of papers citing papers by E. Salinas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Salinas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Salinas. The network helps show where E. Salinas may publish in the future.

Co-authorship network of co-authors of E. Salinas

This figure shows the co-authorship network connecting the top 25 collaborators of E. Salinas. A scholar is included among the top collaborators of E. Salinas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Salinas. E. Salinas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Blank, Stephanie V., Charles Anderson, Kathryn P. Pennington, et al.. (2024). 732P Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical factors in DUO-E. Annals of Oncology. 35. S557–S557. 1 indexed citations
4.
5.
Banerjee, Susana, Kari L. Ring, Michel Fabbro, et al.. (2023). #523 Initial efficacy and safety results from ENGOT-Ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC). Open Repository and Bibliography (University of Liège). A20–A21. 3 indexed citations
6.
Oaknin, Ana, Rebecca Kristeleit, Myong Cheol Lim, et al.. (2022). 2022-LBA-325-ESGO Patients with newly diagnosed ovarian cancer treated with maintenance rucaparib: exploratory biomarker analysis from the phase 3 ATHENA-MONO study (GOG-3020/ENGOT-ov45; NCT03522246). International Journal of Gynecological Cancer. 32. A472–A472. 1 indexed citations
7.
Salinas, E., A.M. Newtson, Bruce A. Smith, et al.. (2019). <p>An integrated prediction model of recurrence in endometrial endometrioid cancers</p>. Cancer Management and Research. Volume 11. 5301–5315. 17 indexed citations
8.
McDonald, Megan, E. Salinas, Eric J. Devor, et al.. (2019). Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer. International Journal of Molecular Sciences. 20(5). 1175–1175. 10 indexed citations
9.
Devor, Eric J., E. Salinas, A.M. Newtson, et al.. (2019). Population Substructure Has Implications in Validating Next-Generation Cancer Genomics Studies with TCGA. International Journal of Molecular Sciences. 20(5). 1192–1192. 9 indexed citations
10.
Salinas, E., A.M. Newtson, Megan McDonald, et al.. (2019). A Prediction Model for Preoperative Risk Assessment in Endometrial Cancer Utilizing Clinical and Molecular Variables. International Journal of Molecular Sciences. 20(5). 1205–1205. 12 indexed citations
11.
Salinas, E., et al.. (2018). Identification of clinical-molecular characteristics associated with recurrent endometrial cancer. Gynecologic Oncology. 149. 184–184. 1 indexed citations
12.
Williams, H., E. Salinas, Megan McDonald, et al.. (2017). The Effect of Weight Based Chemotherapy Dosing in a Cohort of Gynecologic Oncology Patients: A Follow-Up Study. Gynecologic Oncology. 147(1). 190–191. 1 indexed citations
13.
Newtson, A.M., et al.. (2017). Identification of Clinical-Molecular Characteristics Associated with Recurrent Endometrial Cancer. Gynecologic Oncology. 147(1). 200–200. 1 indexed citations
14.
Salinas, E., et al.. (2016). Malignant struma ovarii with insular carcinoma: A case report and literature review. Gynecologic Oncology Reports. 18. 1–3. 5 indexed citations
15.
Salinas, E., A.M. Newtson, Kimberly K. Leslie, & Jesús González Bosquet. (2016). Association analysis of a chemo-response signature identified within The Cancer Genome Atlas aimed at predicting genetic risk for chemo-response in ovarian cancer.. PubMed. 7(1). 41–4. 2 indexed citations
16.
Dai, Donghai, Kristina W. Thiel, E. Salinas, et al.. (2016). Stratification of endometrioid endometrial cancer patients into risk levels using somatic mutations. Gynecologic Oncology. 142(1). 150–157. 6 indexed citations
17.
Salinas, E., Sarah A. Wernimont, Kranti A. Mapuskar, et al.. (2015). Oxidative stress biomarkers and risk of endometrial cancer. Gynecologic Oncology. 137. 160–160. 2 indexed citations
18.
Salinas, E., et al.. (2015). Oxidative stress and genetic variation in endometrial cancer. Gynecologic Oncology. 139(1). 206–206. 1 indexed citations
19.
Baerveldt, George, E. Salinas, & Careen Y. Lowder. (1999). SURGICAL OUTCOME OF UVEITIC GLAUCOMA. Journal of Glaucoma. 8(Supplement 1). S13–S13. 1 indexed citations
20.
Salinas, E., et al.. (1993). Adenocarcinoma de la glándula de Cowper. Revista Argentina de Urología. 58(4). 177–179.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vladimir Nosov Breakdown of academic impact, for papers by Maria Pilar Barretina-Ginesta Breakdown of academic impact, for papers by Ginés Hernández-Cortes Breakdown of academic impact, for papers by Emma Titmuss Breakdown of academic impact, for papers by Kelly K. Foy Breakdown of academic impact, for papers by Anne Sophie V M van den Heerik Breakdown of academic impact, for papers by Daliah Tsoref Breakdown of academic impact, for papers by Alexandra Tyulyandina Breakdown of academic impact, for papers by Zong-Min Fan Breakdown of academic impact, for papers by Eugenia Ortega
Rankless by CCL
2026